Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation

Cayci F. S., Cakar N., Hancer V. S., Uncu N., Acar B., Gur G.

PEDIATRIC NEPHROLOGY, vol.27, no.12, pp.2327-2331, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 12
  • Publication Date: 2012
  • Doi Number: 10.1007/s00467-012-2283-9
  • Journal Name: PEDIATRIC NEPHROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2327-2331
  • Ankara University Affiliated: No

Abstract

Background Hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in childhood. It usually occurs after a prodromal episode of diarrhea and it leads to significant morbidity and mortality during the acute phase. However, cases that start as diarrhea-positive HUS whose renal function fail to recover should be screened for genetic disorders of the complement system, which is called atypical HUS (aHUS).